Everolimus and Temozolomide as First-Line Treatment for Metastatic High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Br. J. Cancer 2023 Oct 23;[EPub Ahead of Print], S Morken, SW Langer, A Sundlöv, LW Vestermark, M Ladekarl, GO Hjortland, JB Svensson, EM Tabaksblat, TM Haslerud, J Assmus, S Detlefsen, A Couvelard, A Perren, H SorbyeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.